

BASi Announces First-of-Its-Kind Pivotal Study with Data Sciences International

The Associated Press

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Dec 7, 2012--BASi(Bioanalytical Systems, Inc.) (NASDAQ: BASI) today announced that it is collaborating with Data Sciences International (DSI), a biomedical research company focused on preclinical systems physiology and pharmacology, to conduct a first-of-its-kind study combining BASi's Culex ® -L automated sampling system with DSI's newest large animal telemetry technology, PhysioTel™ Digital.

In this pivotal study, BASi's Culex ® -L automated in vivo sampling system will simultaneously collect biological samples at pre-programmed intervals while DSI telemetry devices will collect heart rate, blood pressure and other cardiovascular information. Previously, gathering all of these types of data required two separate experiments and only discontinuous data collection was possible.

"By combining Culex ® with telemetry, the automated blood sampling and telemetry (ABST) system will reduce costs, the number of test subjects, subject stress levels, and deliver better data, which will lead to better decisions," said Jacqueline M. Lemke, interim president & CEO and CFO of BASi. "This study lays the groundwork for additional safety pharmacology studies that further complement BASi's long-established and well-respected CRO services expertise." "We're responding to customers' requests for more and better pharmacokinetic data. We know how important these data are for early decision-making in the drug discovery process. Combining DSI's telemetry with BASi's automation is a natural fit," said Dr. Dusty Sarazan, Vice President and CSO of DSI.

About Data Sciences International DSI, with headquarters in St. Paul, Minnesota, is the recognized global leader in physiologic monitoring, offering telemetry, instrumentation, software and services that help advance science. DSI's solutions are tailored to the unique research needs of customers in industries including pharmaceuticals, academia, contract research, biological and chemical defense, medical devices, government and biotechnology. Visit www.datasci.com for more about DSI.

About Bioanalytical Systems, Inc. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASi.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to

BASi Announces First-of-Its-Kind Pivotal Study with Data Sciences International

Published on Medical Design Technology (<http://www.mdtmag.com>)

changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
CONTACT: Company Contact: Bioanalytical Systems, Inc.

Jacqueline Lemke Interim President & CEO and CFO Phone: 765.497.5829
jlemke@BASinc.com or Agency Contact: Berkman Associates Neil Berkman Phone: 310.477.3118 info@berkmanassociates.com
KEYWORD: UNITED STATES NORTH AMERICA INDIANA MINNESOTA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Bioanalytical Systems, Inc. Copyright Business Wire 2012 PUB: 12/07/2012 08:30 AM/DISC: 12/07/2012 08:30 AM
<http://www.businesswire.com/news/home/20121207005082/>

Source URL (retrieved on 03/31/2015 - 5:23pm):

<http://www.mdtmag.com/news/2012/12/basi-announces-first-its-kind-pivotal-study-data-sciences-international>